期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 16, 页码 12022-12048出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00678
关键词
-
资金
- National Natural Science Foundation of China [81922064, 81874290, 81903502]
- Sichuan Science and Technology Program [2020YJ0091, 2020JDRC0053]
- Fundamental Research Funds for the Central Universities [2021SCU12102, 2682020CX56]
The study identified thieno[2,3-d]pyrimidine derivatives as selective inhibitors of VEGFR3, with compound 38k showing the most potent inhibitory effect. 38k effectively suppressed the VEGFR3 signaling pathway, inhibited breast cancer growth, and reduced pulmonary metastasis in mice.
We herein report the identification, structural optimization, and structure-activity relationship of thieno[2,3-d]pyrimidine derivatives as a novel kind of selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors. N-(4-Chloro-3-(trifluoromethyl)phenyl)-4-(6-(4-(4-methylpiperazin-1-yl) phenyl)thieno[2,3-d]pyrimidin-4-yl)piperazine-1-carboxamide (38k) was the most potent VEGFR3 inhibitor (IC50 = 110.4 nM) among developed compounds. Compared with VEGFR1 and VEGFR2, VEGFR3 was approximately 100 times more selective. Here, compound 38k significantly inhibited proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway. Additionally, 38k induced cell apoptosis and a prolonged G1/S-phase in MDA-MB-231 and MDA-MB-436 cells. It also presented acceptable pharmacokinetic characteristics in Sprague-Dawley (SD) rats with an oral bioavailability of 30.9%. In the xenograft model in vivo, 38k effectively inhibited breast cancer growth by suppressing the VEGFR3 signaling pathway. 38k pronouncedly resisted the formation of pulmonary metastatic nodules in mice. Collectively, 38k may be a promising therapeutic agent of metastatic breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据